388 results on '"Bociek, R. Gregory"'
Search Results
2. Data from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
3. Table S2 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
4. Supplementary Methods from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
5. Figure S4 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
6. FIGURE 3 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
7. BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia
8. FIGURE 4 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
9. FIGURE 5 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
10. FIGURE 1 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
11. FIGURE 6 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
12. FIGURE 2 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
13. Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects
14. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
15. Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study
16. Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐ H odgkin lymphoma: A phase I/ II study
17. Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database
18. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL
19. Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation
20. Mortality Patterns Among Recipients of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Myeloma in the Past Three Decades
21. Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II study.
22. Impact of Conditioning Regimen on Outcome of 2-Year Disease-Free Survivors of Autologous Stem Cell Transplantation for Hodgkin Lymphoma
23. Does Functional Imaging Distinguish Nodular Lymphocyte-Predominant Hodgkin Lymphoma From T-Cell/Histiocyte-Rich Large B-Cell Lymphoma?
24. Aggressive Large-Cell Lymphomas
25. Doctor, I’m Sick Again and Again
26. Lung Lesions, Skin Lesions, Brain Lesions … Oh My
27. High-Dose Therapy/Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Marginal Zone Non-Hodgkin Lymphoma
28. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
29. Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?
30. Thrombosis Prophylaxis with Apixaban in Patients Treated with Asparaginase
31. Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma
32. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
33. Two Step Anti-Thymocyte Globulin (ATG) Is Associated with No Severe Acute Graft Versus Host Disease and Favorable Immune Reconstitution Post Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
34. Assessment of Time to CAR-T Cell Therapy and Patients’ Outcomes in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Based on Insurance Status (Public Versus Private) and Distance Traveled to Treatment Center
35. Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes
36. Assessment of Time to Insurance Approval and Distance Traveled in Patients Treated with CAR T-Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
37. Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
38. Assessment of Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) As a Predictor for Higher Level of Care after Discharge for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and Lymphoma
39. Radiotherapy for localized prostate carcinoma: the correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen
40. Hematopoietic growth factors
41. 395 - Two Step Anti-Thymocyte Globulin (ATG) Is Associated with No Severe Acute Graft Versus Host Disease and Favorable Immune Reconstitution Post Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
42. 358 - Assessment of Time to CAR-T Cell Therapy and Patients’ Outcomes in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Based on Insurance Status (Public Versus Private) and Distance Traveled to Treatment Center
43. A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
44. Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
45. Burkitt's Lymphoma: Challenges and Practical Considerations for Modern Therapy
46. Lymphomas with pseudo–double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations
47. A Retrospective Analysis of Transplant and Infectious Outcomes of a Temporal Break between Mobilization and Administration of Melphalan in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant
48. Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study
49. Bariatric Implant–Associated Anaplastic Large-Cell Lymphoma
50. Progress in TP53-Deficient Chronic Lymphocytic Leukemia: More Questions Than Answers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.